Plasma Isopentenyladenine-7-N-Glucoside Detection for Aortic Dissection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current diagnostic methods for acute aortic dissection (AAD) are time-consuming, invasive, and costly, lacking timely prediction capabilities, and existing biomarkers like smMHC, sELAF, and calponin have limited half-lives and high detection costs.

Innovation Solution

Utilization of isopentenyladenine-7-N-glucoside as a plasma biomarker for AAD, employing an online solid phase extraction-liquid chromatography-tandem mass spectrometry method in an auxiliary diagnostic kit for quantitatively detecting the biomarker.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If imaging tools like chest CT are used for diagnostic detection of AAD, then diagnostic accuracy is improved, but detection time is delayed and additional body damage is caused

Engineering Contradiction:

Improvediagnostic accuracyVSAvoiddetection time

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent replaces mechanical imaging tools (chest CT) with a biochemical detection system using liquid chromatography-tandem mass spectrometry to detect isopentenyladenine-7-N-glucoside metabolites in plasma, achieving rapid detection without mechanical intervention delays

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent introduces isopentenyladenine-7-N-glucoside metabolites as intermediary biomarkers that reflect aortic wall stress and damage, enabling indirect but rapid assessment of AAD risk before structural changes become detectable by imaging

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If invasive radiographies are used for diagnostic detection of AAD, then diagnostic accuracy is improved, but body damage increases

Engineering Contradiction:

Improvediagnostic accuracyVSAvoidbody damage

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent substitutes invasive radiographic methods with a non-invasive plasma metabolite analysis system using liquid chromatography-tandem mass spectrometry, eliminating radiation exposure and invasive procedures while maintaining diagnostic capability

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent uses disposable plasma samples for metabolite analysis, replacing expensive and harmful invasive imaging procedures with a simple blood draw that causes minimal trauma and no long-term harm

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

3Reliability

If existing biomarkers like smMHC, sELAF, and calponin are used for AAD detection, then diagnostic capability is improved, but detection cost increases and half-life is limited

Engineering Contradiction:

Improvediagnostic capabilityVSAvoiddetection cost

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent changes the biochemical parameter being measured from proteins (smMHC, sELAF, calponin) to small molecule metabolites (isopentenyladenine-7-N-glucoside), which are more stable, have longer detection windows, and can be measured more cost-effectively using established mass spectrometry methods

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent identifies metabolites that are cheaper to detect and more stable than protein biomarkers, reducing detection costs and extending the useful detection window without requiring expensive specialized assays

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Provides a convenient, low-trauma, and low-cost method for early screening and diagnosis of AAD with high specificity and sensitivity, enabling timely treatment evaluation.

Implementation Method 1

online solid phase extraction-liquid chromatography-tandem mass spectrometry

Methodology Applied

Scientific EffectSolid phase extraction: Adsorption

Implementation Method 2

online solid phase extraction-liquid chromatography-tandem mass spectrometry

Methodology Applied

Scientific EffectLiquid chromatography: Chromatography

Implementation Method 3

online solid phase extraction-liquid chromatography-tandem mass spectrometry

Methodology Applied

Scientific EffectTandem mass spectrometry:

Data Source

PatentUS20250244298A1Acute aortic dissection plasma biomarker and use thereof

Publication Date: 2025.07.31 NANJING MEDICAL UNIV

AI summary

There is a significant difference in the expression level of the metabolic molecule isopentenylenine-7-N-glucoside in a patient with acute aortic dissection (AAD) compared to a healthy population. Therefore, a method for predicting acute aortic dissection in a patient includes quantitatively detecting isopentenyladenine-7-N-glucoside in a plasma sample from the patient. Additionally, a reagent for detecting isopentenyladenine-7-N-glucoside, and an acute aortic dissection auxiliary diagnostic kit that includes this reagent, can be used for screening and diagnosing AAD.